PropertyValue
?:abstract
  • An ongoing pandemic Coronavirus disease (COVID-19), caused by a newly emerged Coronavirus, SARS-CoV-2 has affected millions of people globally. One of the most crucial structural proteins of SARS-CoV-2 is the Spike glycoprotein (S-glycoprotein), for which the first de novo modelling was envisaged by our group in early 2020, and was superimposed to its predecessor SARS-CoV S-glycoprotein, to determine structural divergence, glycosylation and antigenic variation between SARS-CoV-2 and SARS-CoV. S-glycoprotein is involved in binding with the cellular receptor, membrane fusion, internalization via angiotensin-converting enzyme 2 (ACE2) receptor, and tissue tropism. Upon internalization into the target host cells, the viral genome encodes two precursor polypeptides which get processed into 16 mature nonstructural proteins that play a crucial role in replication and transcription of SARS-CoV-2. Currently S-glycoprotein is one of the most vital targets for vaccine and therapeutics development for COVID-19.
is ?:annotates of
?:creator
?:doi
  • 10.1007/s13337-020-00642-7
?:doi
?:journal
  • Virusdisease
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/6c050076aeaa4d0a57f1b17ee98a04f4baef0eb9.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7718591.xml.json
?:pmcid
?:pmid
?:pmid
  • 33313362.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • Chasing COVID-19 through SARS-CoV-2 spike glycoprotein
?:type
?:year
  • 2020-12-05

Metadata

Anon_0  
expand all